BPC-157 / TB-500 — Spray

Product classification

BPC-157 / TB-500 is a dual-compound research preparation containing two structurally distinct synthetic research compounds. It does not have a single molecular formula, molecular weight, or CAS number.

BPC-157 — scientific identity

BPC-157 (CAS 137525-51-0; PubChem CID 108101) is a synthetic pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (one-letter: GEPPPGKPADDAGLV). Molecular formula C₆₂H₉₈N₁₆O₂₂; molecular weight approximately 1,419.55 g/mol (free base). Contains no disulfide bridge; four proline residues — including a consecutive Pro-Pro-Pro triplet — confer stability in acidic environments and resistance to proteolytic degradation. BPC-157 is not a naturally circulating human compound.

TB-500 — scientific identity and naming note

TB-500 is a commercial designation rather than a standardized scientific name, applied to two structurally distinct compounds. Full-length thymosin beta-4 (CAS 77591-33-4) is a 43-amino-acid endogenous actin-regulatory protein with molecular weight approximately 4,963 g/mol; the majority of published scientific literature on thymosin beta-4 biology uses this form. The short actin-binding fragment Ac-LKKTETQ (CAS 885340-08-9) is a 7-residue heptapeptide with molecular weight approximately 889 g/mol; published research specifically on this fragment is more limited. The batch Certificate of Analysis confirms which form is present — a molecular weight near 4,963 Da indicates full-length thymosin beta-4; near 889 Da indicates the short fragment. The two are different compounds and cannot be treated as interchangeable.

Distinction between components

BPC-157 and TB-500 are distinct compounds with different sequences, molecular weights, origins, and proposed mechanisms. Their research profiles overlap in connective-tissue models but they represent independent compounds under investigation and should not be described as variations of the same compound.

Product formats

5mg/5mg: 5mg BPC-157 + 5mg TB-500; 45 sprays per bottle

10mg/10mg: 10mg BPC-157 + 10mg TB-500; 45 sprays per bottle

Per-component per-spray quantities are documented on the product label and batch Certificate of Analysis.

Physical form: Liquid research spray.

Purity: Research-grade. Analytical documentation addresses each component independently.

Analytical documentation

A batch-specific Certificate of Analysis is available on the Longevia Research website, covering identity and purity confirmation for both components individually — including TB-500 form specification — and lot traceability. The substantially different molecular weights of BPC-157 (~1,419 g/mol) and TB-500 (either ~4,963 or ~889 g/mol depending on form) mean mass spectrometric confirmation clearly resolves both compounds and confirms their separate identities in the co-formulated product.

Research-use classification

Research Use Only. Neither component is approved for human or veterinary use. Not intended for administration to humans or animals.

BPC-157 research background and proposed mechanisms

BPC-157 entered the scientific literature through the work of Sikiric, Seiwerth, and colleagues at the University of Zagreb in the early 1990s and has since been investigated in an unusually wide range of rodent model systems over several decades. The most extensively published experimental context is gastrointestinal biology — rodent studies have examined the compound in ethanol-induced gastric lesion models, NSAID-associated gastric damage protocols, ischemia-reperfusion preparations, and experimental colitis models. BPC-157 has also been examined in rodent connective-tissue models of tendon, ligament, and muscle injury — a 2026 systematic review in Pharmaceuticals (Matek et al.; PMID 41754849) consolidated this musculoskeletal literature — and in vascular cell-based assays examining potential interactions with VEGFR2 signaling and eNOS activation, and in rodent neurological models reviewed by Vukojević and colleagues (Neural Regeneration Research, 2022; PMID 34380895). Multiple mechanistic hypotheses have been proposed — including interactions with nitric oxide signaling, VEGFR2-mediated angiogenic cascades, and growth hormone receptor modulation in fibroblasts — none of which represents a definitively validated mechanism at the level of classical pharmacology. A Phase 1 intravenous safety pilot in human volunteers was reported in 2025, representing the first published human study of BPC-157; no completed human efficacy trial exists. Regarding regulatory status: BPC-157 was removed from Category 2 in April 2026, and a PCAC advisory vote of 8-6 on July 23, 2026 recommended 503A listing for an ulcerative colitis indication — an advisory vote only, with formal rulemaking pending. BPC-157 is also listed on the WADA Prohibited List (S0 — Non-Approved Substances).

TB-500 / thymosin beta-4 research background and mechanism

Thymosin beta-4 (Tβ4) is a well-characterized endogenous protein with a defined and extensively studied biochemical function: G-actin sequestration through its LKKTET actin-binding domain. By binding monomeric G-actin, Tβ4 regulates actin filament dynamics, cell motility, and the formation of cellular structures involved in migration — established biochemical observations for the full-length protein. Published research has examined full-length Tβ4 in dermal wound models, cardiac injury models, and corneal healing models in rodents; Sosne, Kleinman, and colleagues published foundational work in ocular surface and wound biology, and Smart, Riley, and colleagues examined Tβ4 in cardiac repair models. RegeneRx Biopharmaceuticals conducted Phase 2 clinical trials of full-length Tβ4 for ophthalmic indications — establishing a human clinical data record for the full-length protein that does not automatically transfer to shorter fragments. Research on the short Ac-LKKTETQ fragment specifically is more limited, and whether this fragment reproduces the full range of full-length Tβ4's biological effects in experimental systems remains under investigation. TB-500 is not FDA-approved and was placed on FDA Category 2 in 2023/early 2024; it was reviewed at the PCAC July 2026 meeting and is listed on the WADA Prohibited List.

Combined research and formulation rationale

A 2026 study published in Joint Diseases and Related Surgery (Sprague-Dawley rat Achilles tendon transection model, 32 animals, four groups of eight; PMID 42542926) examined BPC-157, TB-500, and their combination administered intraperitoneally for four weeks following surgical tendon repair — the principal published peer-reviewed study examining the two compounds specifically in combination. Both individual treatment groups showed improved histopathological parameters relative to control; TB-500 additionally showed biomechanical significance; the combination group was also assessed. This is a single rodent model study with 8 animals per experimental group representing preliminary preclinical evidence from one defined experimental system; it does not establish efficacy, mechanism, or safety in humans. The scientific rationale for studying the two compounds together reflects their non-overlapping proposed mechanisms — BPC-157's vascular and tissue signaling effects and TB-500's actin-regulatory biology — which represent potentially complementary experimental approaches in connective-tissue research contexts. Researchers should be cautious about assuming combination synergy on the basis of mechanistic plausibility and this single preliminary study; evidence for individual compounds should not automatically be interpreted as evidence for the combination.

For a dual-compound spray research product, analytical documentation must establish identity and purity for each component independently. BPC-157 and TB-500 have substantially different molecular weights — approximately 1,419 g/mol versus either approximately 4,963 g/mol (full-length Tβ4) or approximately 889 g/mol (short fragment), depending on form — which means mass spectrometric confirmation clearly resolves the two compounds and confirms their separate identities in a co-formulated product.

Identity confirmation: Each production lot of BPC-157 / TB-500 spray is characterised by mass spectrometric analysis for both components, confirming the observed molecular ions for BPC-157 (GEPPPGKPADDAGLV, approximately 1,419.55 g/mol free base) and for the TB-500 component at its form-appropriate molecular weight. The specific form of TB-500 — full-length Tβ4 or actin-binding fragment — is confirmed on the batch Certificate of Analysis.

Purity assessment: Chromatographic purity analysis quantifies each target compound relative to other UV-absorbing species. For a combination product containing two compounds of substantially different mass, the chromatographic and mass-spectrometric data also confirm that the components are present as expected and are resolved from each other and from synthesis-related impurities.

Batch traceability and Certificate of Analysis: Every production lot of BPC-157 / TB-500 spray (both the 5mg/5mg and 10mg/10mg formats) is traceable to a specific batch. Batch-specific Certificates of Analysis are accessible on the Longevia Research website, covering identity, purity, TB-500 form specification, and lot information. Researchers are encouraged to review current batch documentation — particularly the TB-500 form identification — before use.

Storage: Specific storage conditions and stability information for each format and lot are confirmed on the batch Certificate of Analysis and product labelling.

Longevia Research supplies BPC-157 / TB-500 spray for laboratory and in-vitro research use only. Both the 5mg/5mg and 10mg/10mg formats are intended for qualified researchers and trained laboratory personnel working in appropriate controlled research environments.

BPC-157 / TB-500 is a dual-compound synthetic research product supplied strictly as a laboratory research tool. It is not a drug, not a dietary supplement, not a food or food ingredient, and not a cosmetic. Neither BPC-157 nor TB-500 (in any form) is approved for human or veterinary therapeutic use by the FDA or any other major regulatory authority. Neither compound currently has a lawful 503A pharmaceutical compounding pathway in the United States.

No therapeutic, diagnostic, or efficacy claims are made for this product or its individual components. The preclinical research referenced on this page describes experimental observations from defined cell-based and animal model systems. Those findings do not establish human efficacy, safety, or fitness for any clinical application. The single combination study referenced (PMID 42542926) is a preliminary rodent model study that does not establish combined human therapeutic efficacy.

No dosing instructions, spray-frequency guidance, administration protocols, or usage recommendations are provided. The purchaser assumes full responsibility for lawful acquisition, handling, storage, use, and disposal of this material, and for compliance with all applicable local, state, federal, and institutional regulations.